Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
A single intravitreal injection of 125 μg CB 2782-PEG achieved complete, rapid and sustained pharmacodynamic inhibition (>99%) of complement factor 3 (C3) in non-human primates (NHP), supporting...
-
SOUTH SAN FRANCISCO, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer, will...
-
SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq:CBIO), today announced the initiation of enrollment in a Phase 2b study of dalcinonacog alfa...
-
SOUTH SAN FRANCISCO, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (Nasdaq: CBIO) today announced that the European Commission has awarded orphan designation of its Factor...
-
Completed enrollment of the MarzAA SQ Phase 2 trial and demonstrated safety and clinical efficacy, with >90% reduction in bleeding Completed a full immunogenicity analysis for DalcA, plan to...
-
SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
-
Results from the study demonstrate that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding Enrollment in the Phase 2 portion of the...
-
Results show a four-fold reduction in bleeding time for CB 2679d-GT and a three-fold improvement in clotting activity when compared with an AAV-encoding Padua vector Data presented at the 12th Annual...
-
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address...
-
Oral and poster presentations on updated interim data from the Phase 2/3 trial of MarzAA for the treatment of hemophilia A or B with inhibitors Poster presentation on preclinical data of CB 2679d-GT,...